Evotec rides its risk-sharing model to revenue growth

German contract researcher Evotec posted 9% growth in the first half of 2014, executing on its plan to serve as both CRO and proprietary developer in a hybrid approach to R&D.

The company's revenue came in at about $53.6 million on the half, a leap over last year's $49.2 million. Evotec credits its growth to a slew of payments tied to alliances, licenses and milestones. EVT Execute, the company's CRO arm, brought in $53.2 million, while EVT Innovate, which outlicenses internal candidates, picked up $11.5 million. However, about $10.7 million in intersegment eliminations--in which one business sold services to the other--brought down the revenue total.

For the full year, Evotec expects high single-digit percentage growth in revenue, using some recent deals and acquisitions to flesh out sales as it expands in both its contracting and in-house operations.

Earlier this year, Evotec teamed up with Debiopharm and Convergence Pharmaceuticals in separate deals to handle early-stage drug development work, dovetailing with the company's core business of pursuing risk-splitting projects with drug developing sponsors in exchange for CRO fees and a cut of future profits. That model has attracted collaborators including Bayer, Boehringer Ingelheim, Johnson & Johnson ($JNJ) and Roche ($RHHBY).

And the Hamburg-headquartered company is working to expand EVT Innovate, in March buying up a biopharma asset management company to bring in a pipeline of its own and get to work on some unpartnered assets.

- read the results

Suggested Articles

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.

Aetion has raised $50 million so far, and it plans to enhance its platform to support more complex therapeutic areas and expand its team.

Charles River partners with PathoQuest to offer clients NGS solutions for biologics viral contamination testing and cell-line genetic characterization.